Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated ...

Provide an overview of the current landscape of treatment-naïve CLL treatment options. Where do the BTK inhibitors fit into this landscape? Stay ahead of policy, cost, and value—subscribe to AJMC for ...

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation. Dr ...

Ibrutinib, a BTK inhibitor, is effective in treating relapsed CLL, with combination therapies improving response rates. Combination therapy with ibrutinib and venetoclax, guided by MRD, enhances ...

Besides the presence or absence of specific genetic aberrations, several pieces of evidence point to a key role of the microenvironment in the survival of leukemic cells. CLL cells rapidly undergo ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. We are primarily choosing between targeting ...

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, ...

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.